IDEXX Laboratories, Inc. $IDXX Shares Sold by USA Financial Formulas

USA Financial Formulas decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 44.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,077 shares of the company’s stock after selling 1,650 shares during the quarter. IDEXX Laboratories comprises about 0.3% of USA Financial Formulas’ investment portfolio, making the stock its 28th biggest position. USA Financial Formulas’ holdings in IDEXX Laboratories were worth $1,405,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Virtus Advisers LLC purchased a new position in IDEXX Laboratories during the third quarter worth about $26,000. Park Place Capital Corp purchased a new stake in IDEXX Laboratories in the 4th quarter valued at about $29,000. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories in the 3rd quarter valued at about $31,000. Armstrong Advisory Group Inc. increased its stake in shares of IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after acquiring an additional 19 shares during the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter valued at about $35,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on IDXX shares. Barclays decreased their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Piper Sandler lowered their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Finally, UBS Group cut their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Trading Down 2.6%

NASDAQ IDXX opened at $558.32 on Friday. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The company’s 50 day moving average price is $631.32 and its 200 day moving average price is $661.91. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The firm has a market capitalization of $44.40 billion, a price-to-earnings ratio of 42.72, a PEG ratio of 3.39 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the firm earned $2.53 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 2,693 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the completion of the sale, the executive vice president directly owned 19,899 shares of the company’s stock, valued at $13,163,984.46. The trade was a 11.92% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 45,957 shares of company stock worth $29,862,109. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.